The coagulation laboratory monitoring of Afstyla single-chain FVIII concentrate

Haemophilia

Volumn 23, Issue 5, 2017, Pages e469-e470

  Bowyer, A ^a   Key, N ^b   Dalton, D ^b   Kitchen, S ^a   Makris, M ^a,c  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 8; VON WILLEBRAND FACTOR;

BLOOD ANALYSIS; BLOOD CLOTTING TEST; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MANUFACTURE; DRUG MONITORING; DRUG POTENCY; DRUG SAFETY; GENERAL PRACTITIONER; HEMOPHILIA A; HUMAN; LABORATORY TEST; LETTER; PRIORITY JOURNAL; LABORATORY; PATHOPHYSIOLOGY;

BLOOD COAGULATION TESTS; FACTOR VIII; HEMOPHILIA A; HUMANS; LABORATORIES;

EID: 85021441807     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.13290     Document Type: Letter

References (9)

1. Sommer JM, Moore N, Mcguffie-Valentine B, et al. Comparative field study evaluating the activity of recombinant factor VIII Fc fusion protein in plasma samples at clinical haemostasis laboratories. Haemophilia. 2014;20:294–300.
2. Turecek PL, Romeda-Finger S, Apostol C. A world-wide survey and field study in clinical haemostasis laboratories to evaluate FVIII: C activity assay variability of ADYNOVATE and OBIZUR in comparison with ADVATE. Haemophilia. 2016;22:957–965.
3. Gu J, Ramsey P, Evans V, et al. Evaluation of the activated partial thromboplastin time assay for clinical monitoring of PEGylated recombinant factor VIII (BAY 94-9027) for haemophilia A. Haemophilia. 2014;20:593–600.
4. Bowyer AE, Hillarp A, Ezban M, Persson P, Kitchen S. Measuring factor IX activity of nonacog beta pegol with commercially available one-stage clotting and chromogenic assay kits: a two centre study. J Thromb Haemost. 2016;14:1428–1435.
5. Wilmot HV, Hogwood, J. Gray, E. Recombinant factor IX: discrepancies between one-stage clotting and chromogenic assays. Haemophilia. 2014;20:981–987.
6. Schmidbauer S, Witzel R, Robbel L, Sebastian P, Grammel N, Metzner HJ, Schulte S, et al. Physicochemical characterisation of rVIII-SingleChain, a novel recombinant single-chain factor VIII. Thromb Res. 2015;136:388–395.
7. CSL Behring. Full prescribing information Afstyla antihemophilic factor (recombinant), single chain, 2016.
8. St Ledger K, Fuessner A, Kalina U, et al. Characteristics of rVIII-SingleChain in the one-stage and the chromogenic substrate assay: results of an international field study. Haemophilia. 2016;22(Suppl. 4):59.
9. Collins PW, Chalmers E, Chowdary P, et al. The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO. Haemophilia. 2016;22:487–498.